article thumbnail

FDA approves first vaccine for respiratory syncytial virus

Drug Discovery World

The US Food and Drug Administration (FDA) has approved Pfizer’s bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF) vaccine Abrysvo in individuals 60 years and older. A vaccine to help prevent RSV had been an elusive public health goal for more than half a century.

article thumbnail

FDA approves RSV vaccine to protect babies from birth

Drug Discovery World

The US Food and Drug Administration (FDA) has approved the first vaccine for pregnant individuals to prevent respiratory syncytial virus (RSV) in infants. The FDA approved Abrysvo in May for the prevention of LRTD caused by RSV in individuals 60 years of age and older.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

US approves first mRNA vaccine since Covid-19

Drug Discovery World

The US Food and Drug Administration (FDA) has approved mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection. The vaccine uses the same lipid nanoparticles (LNPs) as the Moderna Covid-19 vaccines.

Vaccine 147
article thumbnail

FDA approves Covid-19 mAb for emergency use in immunocompromised

Drug Discovery World

It is approved in adults and adolescents (12 years of age and older weighing at least 40kg) who are moderate-to-severely immune compromised due to certain medical conditions or receipt of certain immunosuppressive medications or treatments and are unlikely to mount an adequate immune response to Covid-19 vaccination.

article thumbnail

Cancer vaccine shows sustained improvement in survival rates

Drug Discovery World

Cancer vaccine mRNA-4157 (V940) in combination with Keytruda reduced the risk of recurrence or death by 49% in patients with resected high-risk melanoma, according to follow-up data presented at ASCO 2024. Ultimately it will contribute to survival rates improving continually over the next decades and more.” .

Vaccine 147
article thumbnail

US CDC recommends five-in-one meningococcal vaccine

Drug Discovery World

The US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has voted to recommend Pfizer’s Penbraya (meningococcal group A, B, C, W and Y vaccine) for the prevention of the five most common meningococcal serogroups.

Vaccine 130
article thumbnail

Pfizer wins FDA approval of new meningococcal vaccine

BioPharma Drive: Drug Pricing

The clearance of the pentavalent shot Penbraya adds to Pfizer’s infectious disease portfolio as it adjusts to slumping COVID-19 vaccine sales.